retatrutide trial data Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 conducted in the USA retatrutide dosing in trials dose

Anti-aging research with GHK-Cu extends far beyond skin cosmetics

Human Leukocyte Antigen (HLA) - Autoimmunity Risk The test offers insights into genetic susceptibility factors for various pathophysiological mechanisms and environmental triggers associated with the adaptive immune response

Designed as a weekly injection, Mounjaro offers convenient support for weight management

It has helped change the lives of hundreds of individuals who were able to go back to their active lifestyles after treatment

The decision to start a GLP-1 is individual, based on your own risks and benefits

This 5mg vial provides a small research supply of HPLC-verified, high-purity BPC-157, ideal for short pilot studies